Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ann Hsu

Showing results (31-40 of 66) with videos related to

Pageof 7
Sort By:
Parkinsonism & Related Disorders|October 13, 2014
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patientsFabrizio Stocchi, Ann Hsu, Sarita Khanna, et al.
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trialRobert A Hauser, Ann Hsu, Sherron Kell, et al.
Journal for Immunotherapy of Cancer|March 15, 2019
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapyCristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 13, 2005
Development of the cancer therapy satisfaction questionnaire: item generation and content validity testingLinda Abetz, John H Coombs, Dorothy L Keininger, et al.
American Health & Drug Benefits|January 17, 2019
Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint AnalysisYihua Xu, Lavanya Sudharshan, Ming-Ann Hsu, et al.
Arthritis Research & Therapy|March 26, 2021
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinibLaura C Coates, Andrew G Bushmakin, Oliver FitzGerald, et al.
The Journal of Infectious Diseases|January 1, 2004
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudineDale J Kempf, Martin S King, Barry Bernstein, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
American Journal of Physiology. Cell Physiology|January 7, 2011
Functional characterization and modified rescue of novel AE1 mutation R730C associated with overhydrated cation leak stomatocytosisAndrew K Stewart, Prabhakar S Kedar, Boris E Shmukler, et al.
Physiological Reports|March 11, 2022
Erythroid-specific inactivation of Slc12a6/Kcc3 by EpoR promoter-driven Cre expression reduces K-Cl cotransport activity in mouse erythrocytesBoris E Shmukler, Alicia Rivera, Katherine Nishimura, et al.
Pageof 7

Showing results (31-40 of 66) with videos related to

Sort By:
Pageof 7
Parkinsonism & Related Disorders|October 13, 2014
Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patientsFabrizio Stocchi, Ann Hsu, Sarita Khanna, et al.
The Lancet. Neurology|March 15, 2013
Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trialRobert A Hauser, Ann Hsu, Sherron Kell, et al.
Journal for Immunotherapy of Cancer|March 15, 2019
Perception of cure among patients with metastatic genitourinary cancer initiating immunotherapyCristiane Decat Bergerot, Paulo Gustavo Bergerot, Errol J Philip, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 13, 2005
Development of the cancer therapy satisfaction questionnaire: item generation and content validity testingLinda Abetz, John H Coombs, Dorothy L Keininger, et al.
American Health & Drug Benefits|January 17, 2019
Patient Preferences Associated with Therapies for Psoriatic Arthritis: A Conjoint AnalysisYihua Xu, Lavanya Sudharshan, Ming-Ann Hsu, et al.
Arthritis Research & Therapy|March 26, 2021
Relationships between psoriatic arthritis composite measures of disease activity with patient-reported outcomes in phase 3 studies of tofacitinibLaura C Coates, Andrew G Bushmakin, Oliver FitzGerald, et al.
The Journal of Infectious Diseases|January 1, 2004
Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudineDale J Kempf, Martin S King, Barry Bernstein, et al.
Parkinsonism & Related Disorders|September 24, 2013
Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's diseaseRajesh Pahwa, Kelly E Lyons, Robert A Hauser, et al.
American Journal of Physiology. Cell Physiology|January 7, 2011
Functional characterization and modified rescue of novel AE1 mutation R730C associated with overhydrated cation leak stomatocytosisAndrew K Stewart, Prabhakar S Kedar, Boris E Shmukler, et al.
Physiological Reports|March 11, 2022
Erythroid-specific inactivation of Slc12a6/Kcc3 by EpoR promoter-driven Cre expression reduces K-Cl cotransport activity in mouse erythrocytesBoris E Shmukler, Alicia Rivera, Katherine Nishimura, et al.
Pageof 7